{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:47:38Z","timestamp":1773146858442,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2002,11,1]]},"DOI":"10.1038\/sj.bmt.1703698","type":"journal-article","created":{"date-parts":[[2002,11,7]],"date-time":"2002-11-07T12:20:05Z","timestamp":1036671605000},"page":"645-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase I dose-escalation study of etoposide continuous infusion added to busulphan\/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation"],"prefix":"10.1038","volume":"30","author":[{"given":"DS","family":"Ritchie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Szer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AW","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Shuttleworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AP","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2002,11,6]]},"reference":[{"key":"BF1703698_CR1","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","volume":"70","author":"PJ Tutschka","year":"1987","unstructured":"Tutschka PJ . Copelan EA. Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen Blood 1987 70: 1382 1388","journal-title":"Blood"},{"key":"BF1703698_CR2","first-page":"577","volume":"13","author":"G Bandini","year":"1994","unstructured":"Bandini G, Belardinelli A, Rosti G et al. Toxicity of high-dose busulphan and cyclophophamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies Bone Marrow Transplant 1994 13: 577 581","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/10428199409049679","volume":"14","author":"MA Rosenthal","year":"1994","unstructured":"Rosenthal MA, Grigg AP, Sheridan WP . High dose busulphan\/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity Leuk Lymph 1994 14: 279 283","journal-title":"Leuk Lymph"},{"key":"BF1703698_CR4","first-page":"489","volume":"8","author":"WP Vaughan","year":"1991","unstructured":"Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy Bone Marrow Transplant 1991 8: 489 495","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR5","first-page":"2671","volume":"3","author":"AR Zander","year":"1997","unstructured":"Zander AR, Berger C, Kroger N et al. High dose chemotherapy with busulphan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission Clin Cancer Res 1997 3: 2671 2675","journal-title":"Clin Cancer Res"},{"key":"BF1703698_CR6","first-page":"361","volume":"15","author":"P Crilley","year":"1995","unstructured":"Crilley P, Topolsky D, Styler MJ et al. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation Bone Marrow Transplant 1995 15: 361 365","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR7","first-page":"559","volume":"4","author":"TR Spitzer","year":"1989","unstructured":"Spitzer TR, Cottler-Fox M, Torrisi J et al. Escalating doses of etoposide with cyclphosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation Bone Marrow Transplant 1989 4: 559 565","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR8","first-page":"49","volume":"9","author":"V Ratanatharathorn","year":"1992","unstructured":"Ratanatharathorn V, Karanes C, Lum LG et al. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC) Bone Marrow Transplant 1992 9: 49 55","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR9","first-page":"41","volume":"9","author":"RB Geller","year":"1992","unstructured":"Geller RB, Myers S, Devine S et al. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation Bone Marrow Transplant 1992 9: 41 47","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/sj.bmt.1701279","volume":"22","author":"S Jerjis","year":"1998","unstructured":"Jerjis S, Roovers E, Muus P et al. Idarubicin to intensify the conditioning of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission Bone Marrow Transplant 1998 22: 13 19","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.bmt.1702598","volume":"26","author":"N Kroger","year":"2000","unstructured":"Kroger N, Zabelina T, Sonnenberg S et al. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia Bone Marrow Transplant 2000 26: 711 716","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/(SICI)1096-8652(199604)51:4<265::AID-AJH3>3.0.CO;2-U","volume":"51","author":"Y Kanda","year":"1996","unstructured":"Kanda Y, Akiyama H, Tanikawa S et al. Etoposide with\/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team Am J Hematol 1996 51: 265 268","journal-title":"Am J Hematol"},{"key":"BF1703698_CR13","first-page":"15","volume":"4","author":"RJ Jones","year":"1989","unstructured":"Jones RJ, Santos GW . New conditioning regimens for high risk marrow transplants Bone Marrow Transplant 1989 4: (Suppl. 4) 15 17","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR14","first-page":"317","volume":"19","author":"CS Rosenfeld","year":"1991","unstructured":"Rosenfeld CS, Przepiorka D, Schwinghammer TL et al. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease Exp Hematol 1991 19: 317 321","journal-title":"Exp Hematol"},{"key":"BF1703698_CR15","first-page":"423","volume":"13","author":"K Mross","year":"1994","unstructured":"Mross K, Bewermeier P, Reifke J et al. Pharmacokinetics of high dose VP-16: 6-hour infusion versus 34-hour infusion Bone Marrow Transplant 1994 13: 423 430","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/1097-0142(19910101)67:1+<292::AID-CNCR2820671314>3.0.CO;2-7","volume":"67","author":"RH Herzig","year":"1990","unstructured":"Herzig RH . High-dose etoposide and marrow transplantation Cancer 1990 67: (Suppl.) 292 298","journal-title":"Cancer"},{"key":"BF1703698_CR17","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1200\/JCO.1993.11.7.1322","volume":"11","author":"DS Thompson","year":"1993","unstructured":"Thompson DS, Hainsworth JD, Hande KR et al. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I\/II study J Clin Oncol 1993 11: 1322 1328","journal-title":"J Clin Oncol"},{"key":"BF1703698_CR18","first-page":"131","volume":"12","author":"T Ahmed","year":"1993","unstructured":"Ahmed T, Engelking C, Szalyga J et al. Propantheline prevention of mucositis from etoposide Bone Marrow Transplant 1993 12: 131 132","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR19","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.1989.7.9.1288","volume":"7","author":"SI Bearman","year":"1989","unstructured":"Bearman SI, Appelbaum FR, Back A et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma J Clin Oncol 1989 7: 1288 1294","journal-title":"J Clin Oncol"},{"key":"BF1703698_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/sj.bmt.1702443","volume":"25","author":"R Hoyt","year":"2000","unstructured":"Hoyt R, Szer J, Grigg A . Neurological events associated with the infusion of cryopreserved bone marrow and\/or peripheral blood progenitor cells Bone Marrow Transplant 2000 25: 1285 1287","journal-title":"Bone Marrow Transplant"},{"key":"BF1703698_CR21","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood.V79.10.2784.2784","volume":"79","author":"JH Essell","year":"1992","unstructured":"Essell JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulphan\/cyclophosphamide Blood 1992 79: 2784 2788","journal-title":"Blood"},{"key":"BF1703698_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF00689203","volume":"36","author":"SA Holden","year":"1995","unstructured":"Holden SA, Teicher BA, Robinson MF et al. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo Cancer Chemother Pharmacol 1995 36: 165 171","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703698_CR23","first-page":"1350","volume":"147","author":"DL Workman","year":"1995","unstructured":"Workman DL, Clancy J Jr . Phenotypic analysis of pulmonary perivascular mononuclear infiltrates that occur as a direct result of acute lethal graft-versus-host disease describes the onset of interstitial pneumonitis Am J Pathol 1995 147: 1350 1360","journal-title":"Am J Pathol"},{"key":"BF1703698_CR24","first-page":"34","volume":"23","author":"D Porter","year":"1996","unstructured":"Porter D, Boddy A, Thomas H et al. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I\/II committee study Semin Oncol 1996 23: 34 44","journal-title":"Semin Oncol"},{"key":"BF1703698_CR25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1200\/JCO.1997.15.2.766","volume":"15","author":"N Soni","year":"1997","unstructured":"Soni N, Meropol NJ, Pendyala L et al. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer J Clin Oncol 1997 15: 766 772","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703698","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:14:38Z","timestamp":1648077278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,11,1]]}},"alternative-id":["BF1703698"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703698","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,1]]},"assertion":[{"value":"28 February 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}